ADCT ADC Therapeutics SA
8-K Current Report
Filed: February 23, 2026
Health Care
Pharmaceutical PreparationsADC Therapeutics SA (ADCT) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 3.02: Unregistered Sales of Equity Securities
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • HCR royalty deal amended: change-of-control payment slashed from up to $750M to $150M (before 2028) or $200M (after 2028)
- • Post-acquisition royalty obligations can be bought out for $525M (by end 2029) or $750M (by end 2030), less prior royalties paid and CoC payment
Item 3.02 · Unregistered Sales of Equity Securities
- • Warrants issued to HCR for 9,834,776 common shares at $3.8130/share, exercisable through Dec 31, 2030
- • Lock-up on warrant transfers and underlying shares until Dec 31, 2027 — limits near-term selling pressure but caps HCR's flexibility
Other ADC Therapeutics SA 8-K Filings
Get deeper insights on ADC Therapeutics SA
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.